AnaptysBio, Inc. (NASDAQ:ANAB) – Research analysts at Jefferies Group issued their FY2017 EPS estimates for shares of AnaptysBio in a note issued to investors on Thursday. Jefferies Group analyst B. Amin anticipates that the biotechnology company will post earnings per share of ($1.65) for the year. Jefferies Group currently has a “Buy” rating and a $101.00 price objective on the stock. Jefferies Group also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.40) EPS, Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.33) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.40) EPS, FY2018 earnings at ($1.33) EPS, FY2019 earnings at ($2.54) EPS, FY2020 earnings at ($3.27) EPS and FY2021 earnings at ($5.14) EPS.

ANAB has been the topic of several other reports. Credit Suisse Group raised their target price on AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, August 25th. Royal Bank Of Canada lifted their price objective on AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Zacks Investment Research raised AnaptysBio from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research report on Wednesday, August 30th. JMP Securities lifted their price objective on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Finally, Robert W. Baird set a $69.00 price objective on AnaptysBio and gave the company a “buy” rating in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. AnaptysBio presently has an average rating of “Buy” and a consensus price target of $76.25.

TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/13/anaptysbio-inc-anab-to-post-fy2017-earnings-of-1-65-per-share-jefferies-group-forecasts.html.

AnaptysBio (NASDAQ ANAB) opened at $66.50 on Monday. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a 12-month low of $15.17 and a 12-month high of $74.00.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.02.

In related news, major shareholder Holdings A/S Novo sold 178,600 shares of AnaptysBio stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $21.16, for a total transaction of $3,779,176.00. Following the sale, the insider now owns 2,436,332 shares of the company’s stock, valued at approximately $51,552,785.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. DAFNA Capital Management LLC raised its stake in AnaptysBio by 22.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 1,000 shares during the period. New York State Common Retirement Fund raised its stake in AnaptysBio by 21.4% during the 3rd quarter. New York State Common Retirement Fund now owns 8,500 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,500 shares during the period. Teachers Advisors LLC raised its stake in AnaptysBio by 23.4% during the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,807 shares during the period. Alps Advisors Inc. raised its stake in AnaptysBio by 10.0% during the 3rd quarter. Alps Advisors Inc. now owns 20,034 shares of the biotechnology company’s stock valued at $700,000 after purchasing an additional 1,824 shares during the period. Finally, Legal & General Group Plc raised its stake in AnaptysBio by 160.8% during the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,951 shares during the period. 59.04% of the stock is currently owned by institutional investors.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.